Bile acid–farnesoid X receptor–fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial
- 1 September 2021
- journal article
- research article
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 46 (4) , 923-935
Abstract
Background: The gut-liver axis and enterohepatic circulation have gained increasing attention lately. Patients with short bowel syndrome (SBS) are, in fact, human knock-out models that may assist in the understanding of bile acid synthesis and regulation. We evaluated effect of glepaglutide (a long-acting glucagon-like peptide-2 analog) on bile acid synthesis (the enterohepatic circulation of bile acids and liver biochemistry in patients with SBS). Method: In a single-center, double-blinded, dose-finding, crossover phase 2 trial, 18 patients with SBS were randomly assigned to 2 of 3 treatment arms (0.1, 1, and 10 mg) with daily subcutaneous injections of glepaglutide for 3 weeks. The washout period between the 2 treatment periods was 4-8 weeks. Measurements were performed at baseline and at the end of each treatment period and included postprandial plasma samples for fibroblast growth factor 19 (FGF19), 7 alpha-hydroxy-4-cholesten-3-one (C4), total excretion of fecal bile acids, gene expression of farnesoid X receptor (FXR) in intestinal mucosal biopsies, total plasma bile acids, and liver biochemistry. Results: Compared with baseline, the median (interquartile range) postprandial response (area under the curve 0-2h) of FGF19 increased by 150 h x ng/L (41, 195; P = 0.001) and C4 decreased by 82 h x mu g/L (-169, -28; p = 0.010) in the 10-mg dose. FXR gene expression did not change in any of the groups. Alkaline phosphatase significantly decreased. Conclusion: Glepaglutide may stimulate the bile acid/FXR/FGF19 axis, leading to increased plasma concentrations of FGF19. Thereby, glepaglutide may ameliorate the accelerated de novo bile acid synthesis and play a role in the prevention and/or treatment of intestinal failure-associated liver disease.Keywords
This publication has 49 references indexed in Scilit:
- Fibroblast Growth Factor 19 and 7α-Hydroxy-4-Cholesten-3-one in the Diagnosis of Patients With Possible Bile Acid DiarrheaClinical and Translational Gastroenterology, 2012
- A New Mechanism for Bile Acid Diarrhea: Defective Feedback Inhibition of Bile Acid BiosynthesisClinical Gastroenterology and Hepatology, 2009
- Measurement of serum 7α‐hydroxy‐4‐cholesten‐3‐one (or 7αC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography‐tandem mass spectrometryNeurogastroenterology & Motility, 2009
- Some new insights in intestinal failure-associated liver diseaseCurrent Opinion in Organ Transplantation, 2009
- High serum phytosterol levels in short bowel patients on parenteral nutrition supportClinical Nutrition, 2005
- Choline Deficiency Causes Reversible Hepatic Abnormalities in Patients Receiving Parenteral Nutrition: Proof of a Human Choline Requirement: A Placebo‐Controlled TrialJournal of Parenteral and Enteral Nutrition, 2001
- Choline deficiency: A cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementationHepatology, 1995
- Carnitine status of children receiving long-term total parenteral nutrition: A longitudinal prospective studyThe Journal of Pediatrics, 1992
- Low Blood and Plasma Carnitine Levels in Children Receiving Long-Term Parenteral NutritionJournal of Pediatric Gastroenterology and Nutrition, 1990
- ROLE OF THE COLON IN ILEAL-RESECTION DIARRHŒAThe Lancet, 1973